MMW - Fortschritte der Medizin

, Volume 154, Issue 13, pp 63–70

Frühdiagnose, Staging und neue Therapieoptionen

Hepatozelluläres Karzinom
FORTBILDUNG ÜBERSICHT
  • 40 Downloads

Zusammenfassung

Für eine möglichst frühe Diagnostik des Leberzellkarzinoms wurden bei Patienten mit Leberzirrhose in den letzten Jahren nicht invasive bildgebende Diagnosekriterien festgelegt. Zum Staging hat sich die BCLC-Klassifikation etabliert, bei der neben Tumorcharakteristika auch Leberfunktion und Allgemeinzustand berücksichtigt werden. Die Therapieoptionen haben sich mit der Etablierung neuer interventioneller Verfahren und einer systemisch wirksamen Therapie deutlich erweitert.

Keywords - Current therapeutic strategies for hepatocellular carcinoma

Hepatocellular carcinoma diagnostics resection liver transplantation radiofrequency ablation transarterial chemoembolisation radioembolisation Sorafenib 

Literatur

  1. 1.
    El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557–2576.PubMedCrossRefGoogle Scholar
  2. 2.
    Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study. Gastroenterology 2004; 127: 1372–1380.PubMedCrossRefGoogle Scholar
  3. 3.
    Sagmeister M, Renner EL, Mullhaupt B, Wong JB. Simulation of hepatitis C based on a mandatory reporting system. Eur J Gastroenterol Hepatol 2002; 14: 25–34.PubMedCrossRefGoogle Scholar
  4. 4.
    Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003; 348: 1625–1638.PubMedCrossRefGoogle Scholar
  5. 5.
    El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004; 126: 460–468.PubMedCrossRefGoogle Scholar
  6. 6.
    Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208–1236.PubMedCrossRefGoogle Scholar
  7. 7.
    Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004; 130: 417–422.PubMedGoogle Scholar
  8. 8.
    Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020–1022.PubMedCrossRefGoogle Scholar
  9. 9.
    Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology 2009; 49: 658–664.Google Scholar
  10. 10.
    Llovet JM, Chen Y, Wurmbach E, Roayaie S, Fiel MI, Schwartz M, Thung SN, et al. A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology 2006; 131: 1758–1767.PubMedCrossRefGoogle Scholar
  11. 11.
    Hoshida Y, Villanueva A, Kobayashi M, et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 2008; 359: 1995–2004.PubMedCrossRefGoogle Scholar
  12. 12.
    Villanueva A, Hoshida Y, Battiston C, et al. Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Gastroenterology 2011; 140: 1501–1512 e1502.PubMedCrossRefGoogle Scholar
  13. 13.
    Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35: 421–430.PubMedCrossRefGoogle Scholar
  14. 14.
    Clavien PA, Petrowsky H, DeOliveira ML, Graf R. Strategies for safer liver surgery and partial liver transplantation. N Engl J Med 2007; 356: 1545–1559.PubMedCrossRefGoogle Scholar
  15. 15.
    Bruix J, Castells A, Bosch J, et al. Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. Gastroenterology 1996; 111: 1018–1022.PubMedCrossRefGoogle Scholar
  16. 16.
    Fan ST. Methods and related drawbacks in the estimation of surgical risks in cirrhotic patients undergoing hepatectomy. Hepatogastroenterology 2002; 49: 17–20.Google Scholar
  17. 17.
    Hofmann WP, Radle J, Moench C, Bechstein W, Zeuzem S. [Prediction of perioperative mortality in patients with advanced liver disease and abdominal surgery by the use of different scoring systems and tests]. Z Gastroenterol 2008; 46: 1283–1289.PubMedCrossRefGoogle Scholar
  18. 18.
    Fan ST, Lo CM, Liu CL, Lam CM, Yuen WK, Yeung C, Wong J. Hepatectomy for hepatocellular carcinoma: toward zero hospital deaths. Ann Surg 1999; 229: 322–330.PubMedCrossRefGoogle Scholar
  19. 19.
    Llovet JM, Schwartz M, Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis 2005; 25: 181–200.PubMedCrossRefGoogle Scholar
  20. 20.
    Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693–699.PubMedCrossRefGoogle Scholar
  21. 21.
    Clavien PA, Lesurtel M, Bossuyt PM, Gores GJ, Langer B, Perrier A. Recommendations for Liver Transplantation for HCC: an International Consensus Conference Report. Lancet Oncology 2011 Oct 31 [Epub ahead of print] PMID: 22047762.Google Scholar
  22. 22.
    Mazzaferro V, Llovet JM, Miceli R, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009; 10: 35–43.PubMedCrossRefGoogle Scholar
  23. 23.
    Yao FY, Kinkhabwala M, LaBerge JM, et al. The impact of pre-operative loco-regional therapy on outcome after liver transplantation for hepatocellular carcinoma. Am J Transplant 2005; 5: 795–804.PubMedCrossRefGoogle Scholar
  24. 24.
    Lesurtel M, Mullhaupt B, Pestalozzi BC, Pfammatter T, Clavien PA. Transarterial chemoembolization as a bridge to liver transplantation for hepatocellular carcinoma: an evidence-based analysis. Am J Transplant 2006; 6: 2644–2650.PubMedCrossRefGoogle Scholar
  25. 25.
    Zimmerman MA, Ghobrial RM, Tong MJ, Hiatt JR, Cameron AM, Hong J, Busuttil RW. Recurrence of hepatocellular carcinoma following liver transplantation: a review of preoperative and postoperative prognostic indicators. Arch Surg 2008; 143: 182–188; discussion 188.PubMedCrossRefGoogle Scholar
  26. 26.
    Wang JH, Wang CC, Hung CH, Chen CL, Lu SN. Survival comparison between surgical resection and radiofrequency ablation for patients in BCLC very early/early stage hepatocellular carcinoma. J Hepatol 2011 in press.Google Scholar
  27. 27.
    Livraghi T, Meloni F, Di Stasi M, Rolle E, Solbiati L, Tinelli C, Rossi S. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice? Hepatology 2008; 47: 82–89.PubMedCrossRefGoogle Scholar
  28. 28.
    Chen MS, Li JQ, Zheng Y, et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg 2006; 243: 321–328.PubMedCrossRefGoogle Scholar
  29. 29.
    Burak KW, Bathe OF. Is surgical resection still the treatment of choice for early hepatocellular carcinoma? J Surg Oncol 2011; 104: 1–2.PubMedCrossRefGoogle Scholar
  30. 30.
    Callstrom MR, Charboneau JW. Technologies for ablation of hepatocellular carcinoma. Gastroenterology 2008; 134: 1831–1835.PubMedCrossRefGoogle Scholar
  31. 31.
    Bruix J, Sala M, Llovet JM. Chemoembolization for hepatocellular carcinoma. Gastroenterology 2004; 127: S179–188.PubMedCrossRefGoogle Scholar
  32. 32.
    Tsochatzis EA, Germani G, Burroughs AK. Transarterial chemoembolization, transarterial chemotherapy, and intra-arterial chemotherapy for hepatocellular carcinoma treatment. Semin Oncol 2010; 37: 89–93.PubMedCrossRefGoogle Scholar
  33. 33.
    Lewandowski RJ, Geschwind JF, Liapi E, Salem R. Transcatheter intraarterial therapies: rationale and overview. Radiology 2011; 259: 641–657.PubMedCrossRefGoogle Scholar
  34. 34.
    Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003; 37: 429–442.PubMedCrossRefGoogle Scholar
  35. 35.
    Varela M, Real MI, Burrel M, et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 2007; 46: 474–481.PubMedCrossRefGoogle Scholar
  36. 36.
    Lencioni R, Zou J, Leberre M, Meinhardt G, Voliotis D, Bruix J, Llovet JM. Sorafenib (SOR) or placebo (PL) in combination with transarterial chemoembolization (TACE) for intermediate-stage hepatocellular carcinoma (SPACE). J Clin Oncol 2010; 28:suppl; abstr TPS178.Google Scholar
  37. 37.
    Salem R, Lewandowski RJ, Mulcahy MF, et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 2010; 138: 52–64.PubMedCrossRefGoogle Scholar
  38. 38.
    Hilgard P, Hamami M, Fouly AE, et al. Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatology 2010; 52: 1741–1749.PubMedCrossRefGoogle Scholar
  39. 39.
    Salem R, Lewandowski RJ, Kulik L, et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 2011; 140: 497–507 e492.PubMedCrossRefGoogle Scholar
  40. 40.
    Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378–390.PubMedCrossRefGoogle Scholar
  41. 41.
    Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25–34.PubMedCrossRefGoogle Scholar
  42. 42.
    Marrero JA, Lencioni R, Kudo M, Ye S, Nakajima K, Cihon F, Venook AP. Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of its Treatment with Sorafenib (GIDEON) second interim analysis in more than 1,500 patients: Clinical findings in patients with liver dysfunction. J Clin Oncol 2011; 29: Abstr 4001.Google Scholar
  43. 43.
    Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30: 52–60.PubMedCrossRefGoogle Scholar
  44. 44.
    Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 2008; 48 Suppl 1: S20–37.PubMedCrossRefGoogle Scholar
  45. 45.
    Faivre S, Bouattour M, Raymond E. Novel molecular therapies in hepatocellular carcinoma. Liver Int 2011; 31 Suppl 1: 151–160.PubMedCrossRefGoogle Scholar
  46. 46.
    Villanueva A, Llovet JM. Targeted therapies for hepatocellular carcinoma. Gastroenterology 2011; 140: 1410–1426.PubMedCrossRefGoogle Scholar
  47. 47.
    Cheng A, Kang Y, Lin D, et al. Phase III trial of sunitinib (Su) versus sorafenib (So) in advanced hepatocellular carcinoma (HCC). J Clin Oncol 2011; 29: Abstr 4000.Google Scholar
  48. 48.
    Abou-Alfa GK, Johnson P, Knox JJ, et al. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA 2010; 304: 2154–2160.PubMedCrossRefGoogle Scholar
  49. 49.
    Poon RT. Prevention of recurrence after resection of hepatocellular carcinoma: A daunting challenge. Hepatology 2011; 54(3): 757–9.PubMedCrossRefGoogle Scholar

Copyright information

© Urban & Vogel 2012

Authors and Affiliations

  1. 1.Schwerpunkt Hepatologie Medizinische Klinik und Poliklinik IIUniversitätsklinikum WürzburgWürzburgDeutschland

Personalised recommendations